PAXLOVID (COPACKAGED)

Growth

nirmatrelvir and ritonavir

Pfizer
NDAORALTABLETPriority Review
Approved
May 2023
Lifecycle
Growth
Competitive Pressure
0/100

Mechanism of Action

2 (SARS-CoV-2) antiviral drug [see ]. Ritonavir is an HIV-1 protease inhibitor but is not active against SARS-CoV-2 M. Ritonavir inhibits the CYP3A-mediated metabolism of nirmatrelvir, resulting in increased plasma concentrations of nirmatrelvir.

Indications (3)

mild-to-moderate coronavirus disease 2019 (COVID-19) in adultsincluding hospitalizationdeath

Loss of Exclusivity

LOE Date
Oct 31, 2041
190 months away
Patent Expiry
Oct 31, 2041
Exclusivity Expiry
May 25, 2028

Patent Records (2)

Patent #ExpiryTypeUse Code
11351149
Aug 5, 2041
SubstanceProduct
U-3629
11541034
Oct 31, 2041
U-3629
Company
Pfizer
Pfizer
NEW YORK, NY
616 open jobs
External Resources
DailyMed
Full prescribing information
FDA Drugs@FDA
FDA approval history
RxNorm
Drug nomenclature & identifiers